ENST00000506722.5:c.-40+9357C>T
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The ENST00000506722.5(ANK2):c.-40+9357C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.293 in 845,392 control chromosomes in the GnomAD database, including 37,248 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.30 ( 6917 hom., cov: 32)
Exomes 𝑓: 0.29 ( 30331 hom. )
Consequence
ANK2
ENST00000506722.5 intron
ENST00000506722.5 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: 0.378
Publications
2 publications found
Genes affected
ANK2 (HGNC:493): (ankyrin 2) This gene encodes a member of the ankyrin family of proteins that link the integral membrane proteins to the underlying spectrin-actin cytoskeleton. Ankyrins play key roles in activities such as cell motility, activation, proliferation, contact and the maintenance of specialized membrane domains. Most ankyrins are typically composed of three structural domains: an amino-terminal domain containing multiple ankyrin repeats; a central region with a highly conserved spectrin binding domain; and a carboxy-terminal regulatory domain which is the least conserved and subject to variation. The protein encoded by this gene is required for targeting and stability of Na/Ca exchanger 1 in cardiomyocytes. Mutations in this gene cause long QT syndrome 4 and cardiac arrhythmia syndrome. Multiple transcript variants encoding different isoforms have been described. [provided by RefSeq, Dec 2011]
ANK2 Gene-Disease associations (from GenCC):
- complex neurodevelopmental disorderInheritance: AD Classification: DEFINITIVE, MODERATE Submitted by: Ambry Genetics, ClinGen
- Brugada syndromeInheritance: AD Classification: LIMITED, NO_KNOWN Submitted by: Genomics England PanelApp, ClinGen
- catecholaminergic polymorphic ventricular tachycardiaInheritance: AD Classification: LIMITED, NO_KNOWN Submitted by: ClinGen, Genomics England PanelApp
- heart conduction diseaseInheritance: AD Classification: LIMITED Submitted by: Genomics England PanelApp
- neurodevelopmental disorderInheritance: AD Classification: LIMITED Submitted by: G2P
- cardiac arrhythmia, ankyrin-B-relatedInheritance: Unknown, AD Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics
- long QT syndromeInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.88).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.334 is higher than 0.05.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| ANK2 | ENST00000506722.5 | c.-40+9357C>T | intron_variant | Intron 1 of 46 | 1 | ENSP00000421067.1 | ||||
| ANK2 | ENST00000672209.1 | c.-40+9357C>T | intron_variant | Intron 1 of 47 | ENSP00000499982.1 | |||||
| ANK2 | ENST00000673298.1 | c.-40+9357C>T | intron_variant | Intron 1 of 46 | ENSP00000500245.1 |
Frequencies
GnomAD3 genomes AF: 0.299 AC: 45406AN: 151940Hom.: 6900 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
45406
AN:
151940
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.292 AC: 202274AN: 693334Hom.: 30331 Cov.: 9 AF XY: 0.294 AC XY: 108480AN XY: 368670 show subpopulations
GnomAD4 exome
AF:
AC:
202274
AN:
693334
Hom.:
Cov.:
9
AF XY:
AC XY:
108480
AN XY:
368670
show subpopulations
African (AFR)
AF:
AC:
4816
AN:
17816
American (AMR)
AF:
AC:
11405
AN:
33936
Ashkenazi Jewish (ASJ)
AF:
AC:
5513
AN:
17906
East Asian (EAS)
AF:
AC:
11956
AN:
35978
South Asian (SAS)
AF:
AC:
19876
AN:
61170
European-Finnish (FIN)
AF:
AC:
16408
AN:
48582
Middle Eastern (MID)
AF:
AC:
1367
AN:
4070
European-Non Finnish (NFE)
AF:
AC:
120325
AN:
439812
Other (OTH)
AF:
AC:
10608
AN:
34064
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.495
Heterozygous variant carriers
0
6924
13848
20772
27696
34620
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
1772
3544
5316
7088
8860
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.299 AC: 45462AN: 152058Hom.: 6917 Cov.: 32 AF XY: 0.301 AC XY: 22377AN XY: 74318 show subpopulations
GnomAD4 genome
AF:
AC:
45462
AN:
152058
Hom.:
Cov.:
32
AF XY:
AC XY:
22377
AN XY:
74318
show subpopulations
African (AFR)
AF:
AC:
11354
AN:
41490
American (AMR)
AF:
AC:
5069
AN:
15274
Ashkenazi Jewish (ASJ)
AF:
AC:
1063
AN:
3468
East Asian (EAS)
AF:
AC:
1798
AN:
5172
South Asian (SAS)
AF:
AC:
1580
AN:
4822
European-Finnish (FIN)
AF:
AC:
3570
AN:
10558
Middle Eastern (MID)
AF:
AC:
86
AN:
294
European-Non Finnish (NFE)
AF:
AC:
20030
AN:
67960
Other (OTH)
AF:
AC:
703
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
1609
3218
4828
6437
8046
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
460
920
1380
1840
2300
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1351
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.